BACKGROUND: In @entity1 with @entity385 origin, @entity117 , @entity1397 , or a combination of @entity117 and @entity4341 are recommended for the prevention of a recurrent @entity64 . The purpose of this study was to examine the risk of @entity548 or recurrent @entity64 associated with these three treatments. METHODS: @entity1 who were discharged with first-time @entity385 from 2007-2010, with no history of @entity955 were identified from Danish nationwide registries. Hazard ratios (HRs) and 1-year risks of recurrent @entity385 and @entity548 were calculated for each antiplatelet regimen. RESULTS: Among @entity1 discharged after first-time @entity385 , 3043 @entity1 were treated with @entity117 , 12,295 with a combination of @entity117 and @entity4341 , and 3885 with @entity1397 . @entity2166 for @entity1397 versus the combination of @entity117 and @entity4341 were 1.02 (95  % confidence interval [CI]: 0.89-1.17) for @entity385 and 1.06 (95  % CI: 0.83-1.35) for @entity548 . @entity2166 for @entity117 versus the combination of @entity117 and @entity4341 were 1.48 (95  % CI: 1.31-1.67) for @entity64 and 1.47 (95  % CI: 1.18-1.82) for @entity548 . @entity1397 versus @entity117 yielded HRs of 0.69 (95  % CI: 0.59-0.81) and 0.72 (95  % CI: 0.55-0.96) for @entity64 and @entity548 , respectively. The 1-year predicted risks associated with @entity117 , the combination of @entity117 and @entity4341 , and @entity1397 were 11.1 (95  % CI: 10.2-12.2), 7.7 (95  % CI: 7.3-8.3), and 8.0 (95  % CI: 6.9-8.7) for @entity385 , respectively; while, the risks for @entity548 were 3.4 (95  % CI: 2.8-3.9), 2.4 (95  % CI: 2.1-2.7), and 2.4 (95  % CI: 1.9-2.9), respectively. CONCLUSION: @entity1397 and the combination of @entity117 and @entity4341 were associated with similar risks for recurrent @entity385 and @entity548 ; whereas @entity117 was associated with higher risks for both @entity385 and @entity548 . The latter finding may partially be explained by selection bias.

Comparison of antiplatelet regimens in secondary XXXX prevention: a nationwide cohort study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['Clopidogrel', 'clopidogrel'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['acetylsalicylic acid'] @entity4341 :: ('MESH:D004176', 'Chemical') :: ['dipyridamole'] @entity2166 :: ('MESH:D000275', 'Disease') :: ['Adjusted HRs'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke', 'ischemic stroke of non-cardioembolic']
@entity64 :: (MESH:D020521,Disease) :: ['stroke']
